BioCryst Pharmaceuticals, Inc. (BCRX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 10.78 |
| Open | 10.80 |
| Bid | 10.56 x 1100 |
| Ask | 10.70 x 1100 |
| Day's Range | 10.56 - 10.97 |
| 52 Week Range | 7.61 - 19.99 |
| Volume | |
| Avg. Volume | 2,918,603 |
| Market Cap | 1.904B |
| Beta (5Y Monthly) | 2.05 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.09 |
| Earnings Date | Feb 21, 2023 - Feb 27, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.30 |
- GlobeNewswire
BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema
RESEARCH TRIANGLE PARK, N.C., Jan. 26, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first patient in the pivotal APeX-P trial evaluating oral, once-daily ORLADEYO® (berotralstat) in pediatric hereditary angioedema (HAE) patients who are 2 to <12 years of age. “Today’s announcement marks a very important step in our continuing efforts to reduce the burden of therapy for people living with HAE around the world with oral, once-daily OR
- GlobeNewswire
BioCryst Selects Swixx BioPharma as Commercial Partner for ORLADEYO® (berotralstat) in Central and Eastern Europe
RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered into a collaboration with Swixx BioPharma AG to commercialize ORLADEYO® (berotralstat) in Central and Eastern Europe (CEE). “We continue to build partnerships with companies that have deep expertise in commercializing rare disease therapies as we advance our mission of bringing ORLADEYO to patients living with hereditary angioedema around the world
- Simply Wall St.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX): Is Breakeven Near?
We feel now is a pretty good time to analyse BioCryst Pharmaceuticals, Inc.'s ( NASDAQ:BCRX ) business as it appears...
